Analysts Expect Celldex Therapeutics, Inc. (CLDX) Will Post Earnings of -$0.12 Per Share

Brokerages expect that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will post earnings of ($0.12) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Celldex Therapeutics’ earnings, with estimates ranging from ($0.17) to ($0.07). Celldex Therapeutics reported earnings per share of ($0.14) during the same quarter last year, which suggests a positive year over year growth rate of 14.3%. The company is scheduled to announce its next quarterly earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that Celldex Therapeutics will report full year earnings of ($1.15) per share for the current financial year, with EPS estimates ranging from ($1.26) to ($1.06). For the next year, analysts anticipate that the business will post earnings of ($0.53) per share, with EPS estimates ranging from ($0.72) to ($0.26). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Celldex Therapeutics.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. Celldex Therapeutics had a negative return on equity of 47.40% and a negative net margin of 1,159.26%. The company had revenue of $2.76 million for the quarter, compared to analyst estimates of $2.70 million.

Several research analysts have weighed in on CLDX shares. HC Wainwright set a $2.00 target price on Celldex Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 9th. Zacks Investment Research raised Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Tuesday, June 19th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Celldex Therapeutics in a research report on Friday, August 10th. Finally, Cowen reaffirmed a “hold” rating on shares of Celldex Therapeutics in a research report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $3.75.

CLDX stock traded down $0.01 during mid-day trading on Friday, hitting $0.44. The stock had a trading volume of 2,406,200 shares, compared to its average volume of 2,238,955. Celldex Therapeutics has a 1-year low of $0.40 and a 1-year high of $3.09. The firm has a market cap of $73.26 million, a P/E ratio of -0.55 and a beta of 2.29.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of Celldex Therapeutics by 1.7% during the 1st quarter. BlackRock Inc. now owns 10,097,481 shares of the biopharmaceutical company’s stock valued at $23,527,000 after acquiring an additional 166,780 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Celldex Therapeutics by 74.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,167,585 shares of the biopharmaceutical company’s stock valued at $9,710,000 after acquiring an additional 1,783,765 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Celldex Therapeutics by 27.7% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 900,185 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 195,147 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Celldex Therapeutics during the 2nd quarter valued at about $322,000. Finally, Acadian Asset Management LLC increased its holdings in shares of Celldex Therapeutics by 378.4% during the 2nd quarter. Acadian Asset Management LLC now owns 1,157,880 shares of the biopharmaceutical company’s stock valued at $583,000 after acquiring an additional 915,863 shares during the last quarter. 33.54% of the stock is currently owned by institutional investors and hedge funds.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.

Featured Article: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply